Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of head and neck cancer

A technology of cancer and radiation therapy, applied in the direction of antibody medical ingredients, medical preparations containing active ingredients, anti-animal/human immunoglobulin, etc.

Pending Publication Date: 2020-11-27
INNATE PHARMA SA
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, since many HNSCC patients receive different courses of treatment despite currently approved therapies, there remains a need in the art to identify patient populations that would most benefit from treatment with immunotherapeutic agents

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of head and neck cancer
  • Treatment of head and neck cancer
  • Treatment of head and neck cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0156] Example 1 - Response case of cetuximab-resistant patient to repeated injections of monalizumab in combination with cetuximab for HNSCC

[0157] The phase 1b / 2 trial of IPH2201 and cetuximab was conducted in patients with human papillomavirus (HPV)(+) and HPV(-) squamous cell carcinoma of the head and neck. Although cetuximab following platinum-based therapy is approved for HNSCC, it has limited activity in this setting (12% response rate). A clinical trial evaluating the efficacy of monalizumab combined with cetuximab in the treatment of HNSCC. Monalizumab (see WHO Drug Information [WHO Drug Information] Volume 30, No.1, 2016), also known as IPH2201, is a neutralizing anti-NKG2A antibody with SEQ ID NO The heavy chain amino acid sequence shown in SEQ ID NO:2 and the light chain amino acid sequence shown in SEQ ID NO:7.

[0158] The inclusion criteria are as follows:

[0159] Age ≥ 18 years old

[0160] 1. Histologically or cytologically confirmed HPV (+) or HPV ( -...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to the use of NKG2A-targeting agents for the treatment of cancers, notably head and neck cancers, in a patient having received prior treatment with cetuximab. This invention also provides advantageous combination regimens for use with NKG2A-targeting agents for the treatment of cancers.

Description

technical field [0001] The present invention relates to the use of NKG2A-targeting agents for the treatment of cancer, especially head and neck cancer. The present invention also provides advantageous combination regimens using NKG2A-targeting agents for cancer therapy. Background technique [0002] Natural killer (NK) cell activity is regulated by complex mechanisms involving activating and inhibitory signals. A number of different NK-specific receptors have been identified that play an important role in NK cell-mediated recognition and killing of HLA class I deficient target cells. Natural cytotoxicity receptor (NCR) refers to a class of activated receptor proteins specifically expressed in NK cells and the genes expressing them. Examples of NCRs include NKp30, NKp44 and NKp46 (see eg Lanier (2001) Nat Immunol 2:23-27). Another important activating receptor involved in NK cell lysis of target cells is NKG2D. NKG2D recognizes MICA / B and ULBP protein families of class I ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K39/395A61P35/00
CPCC07K16/2803C07K16/2863C07K16/30C07K2317/24C07K2317/76A61K2039/507A61K2039/55A61P35/00C07K2317/52A61K2039/545C07K2317/565
Inventor A·布瓦耶-沙马尔P·多迪永R·B·科昂
Owner INNATE PHARMA SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com